Comment
Author: Admin | 2025-04-28
Best for you.Toujeo does not currently have any biosimilars.7. Trulicity (dulaglutide)Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. Trulicity, from Eli Lilly, is approved as a once-weekly subcutaneous (under the skin) injection used to improve blood sugar levels, along with diet and exercise, in adults with type 2 diabetes.Its use has also been expanded to help reduce the risk of serious heart problems such as heart attack or stroke in adults with type 2 diabetes with established cardiovascular (heart) disease or multiple cardiovascular risk factors (for example: smoking, obesity, high blood pressure, elevated cholesterol (LDL), family history).Trulicity comes in several strengths as a pen device with an automatic injector. Once-weekly dosing may be a big advantage for many patients. Another advantage to GLP-1 receptor agonists is a reduced risk for low blood sugar (hypoglycemia), especially compared to insulin or sulfonylureas.GLP-1 receptor agonists should not be used by anyone with a personal or family history of certain types of thyroid cancer. A boxed warning exists for all GLP-1 receptor agonists for possible thyroid tumors, including cancer.Common side effects with Trulicity include:nauseavomitingdiarrheastomach (abdominal) paindecreased appetite.Trulicity is in the same group of drugs as Saxenda, Bydureon, Victoza, Rybelsus, Wegovy and Ozempic.Mounjaro and Zepbound, both tirzepatide products, are dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) agonists approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound).8. Victoza (liraglutide)Victoza (liraglutide) from Novo Nordisk is also a glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic) indicated to improve glycemic control in adults with type 2 diabetes mellitus. It is in the same class of drug as Trulicity, Ozempic, Rybelsus and Bydureon BCise.Type 2 diabetes patients have a four times greater risk of developing heart disease, which is the leading cause of disease and death in patients with type 2 diabetes.Although Victoza was originally approved in January, 2010, in 2017 it gained a new labeled indication to reduce the risk of heart attack, stroke and cardiovascular (CV) death in adults with type 2 diabetes and established heart (cardiovascular) disease. Victoza demonstrated a life-saving benefit that included a 22% reduction in cardiovascular death and a 15% reduction in all-cause death.In June 2019, it was also approved for the treatment of pediatric patients 10 years or older with type 2 diabetesIn studies, the most common side effects leading to the discontinuation of Victoza were gastrointestinal (stomach) events, which are common
Add Comment